|
Abbott's XIENCE Xpedition Everolimus Eluting Coronary Stent System receives …
News-Medical.net Abbott (NYSE: ABT) today announced that the XIENCE Xpedition™ Everolimus Eluting Coronary Stent System received CE Mark in Europe for the treatment of coronary artery disease. The company is launching the product immediately in CE Mark countries. Abbott Reveals CE Mark Approval For XIENCE Xpedition Everolimus Eluting … Abbott Announces CE Mark and European Launch of Next-Generation XIENCE … Updated Xience nets CE mark, with shorter DAPT time |
